Oxaliplatin Hikma

Oxaliplatin, the active ingredient in Oxaliplatin Hikma, is a platinum‑based chemotherapy agent presented as a sterile powder for intravenous infusion use. It is employed in the treatment of colorectal cancer, typically in combination regimens for adult patients. GNH USA supplies Oxaliplatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH USA supplies Oxaliplatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic that interferes with DNA replication in gastrointestinal malignancies.

- Colorectal cancer: used in adjuvant or metastatic settings to improve progression‑free survival. - Gastric cancer: combined with fluoropyrimidines for enhanced response rates. - Pancreatic cancer: part of multi‑drug regimens to increase tumor control. - Small‑cell lung cancer: employed in select protocols to augment cytotoxic effect. - Ovarian cancer: used off‑label within clinical trials to explore efficacy. - Esophageal cancer: incorporated in combination therapy for advanced disease.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, requiring monitoring during therapy.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhea: watery stools that may require antidiarrheal support. - Fatigue: generalized tiredness affecting daily activities. - Thrombocytopenia: reduced platelet count increasing bleed risk. - Neutropenia: lowered neutrophil levels predisposing to infection.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Acute pulmonary toxicity: dyspnea or infiltrates on imaging. - Hemolytic‑uremic syndrome: rare renal and hematologic complication. - Cardiotoxicity: arrhythmias or myocardial injury. - Severe electrolyte disturbances: hypomagnesemia or hypokalemia. - Persistent neuropathy: long‑lasting sensory deficits after treatment.

Oxaliplatin requires careful assessment before and during treatment to minimize risks.

- Renal function: assess creatinine clearance before initiation and monitor regularly. - Hepatic function: evaluate liver enzymes, especially in patients with metastasis. - Pre‑existing neuropathy: consider dose adjustments if baseline neuropathy is present. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risk. - Concomitant ototoxic drugs: monitor auditory function when used together. - Store at below 25°C: keep in original container, protect from moisture and light.

Oxaliplatin can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increased risk of nephrotoxicity. - High‑dose vitamin C infusions: may reduce platinum‑DNA binding. - Live vaccines: immunosuppression may diminish vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): heightened bleeding risk due to thrombocytopenia. - Antiemetics (5‑HT3 antagonists): may require dose adjustments for optimal control. - CYP450 inducers (rifampicin): potential alteration of drug clearance. - NSAIDs: increased risk of gastrointestinal irritation. - Diuretics: monitor electrolytes for additive hypomagnesemia.